Arcutis Biotherapeutics’ (ARQT) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a report published on Friday,Benzinga reports. The firm currently has a $20.00 target price on the stock. A number of other brokerages also recently commented on ARQT. Mizuho upped their price objective on shares of Arcutis Biotherapeutics […]
Needham & Company LLC reissued their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a report published on Friday,Benzinga reports. The firm currently has a $20.00 target price on the stock. A number of other brokerages also recently commented on ARQT. Mizuho upped their price objective on shares of Arcutis Biotherapeutics […]
